

Siemens Healthineers Expands Peanut Testing to Help Improve Allergy Sufferers' Quality of Life; Other New Component Allergens Available, too

- **Global estimates suggest 30-40% of the population suffers from one or more allergies.**
- **Peanut allergies are the leading cause of fatal food-related anaphylaxis.**
- **Personalized allergy insights gained from component testing can help improve quality of life.**

Siemens Healthineers has expanded its 3gAllergy assay menu with nine new component allergens, including six targeting peanuts, the leading cause of fatal food-related anaphylaxis.¹ Also now available are components derived from house dust mites and wheat. Component-level insights empower clinicians to better distinguish between high-risk sensitizations and more benign exposures, ultimately helping to guide more personalized and informed patient care. These additions bring the total allergen count to over 500 available on the IMMULITE 2000 XPi System.²

Testing for specific allergy components offers valuable information for clinicians and those suffering from allergies. It is estimated that 30-40% of the global population suffer from one or more allergies.³ While standard allergy tests confirm the presence of an allergy, component-level insights support physicians in developing more personalized allergy management strategies. This approach helps improve quality of life by minimizing potentially unnecessary restrictions. For example, instead of avoiding peanuts entirely, individuals living with allergies can make more precise choices relative to their specific risks of an adverse outcome.

"Understanding the root causes of allergies can help alleviate anxiety and be the difference between reasonable lifestyle modifications or life-saving precautions," said Duncan Porter, head of Immulite, Plasma Proteins, and Syva, the allergy testing and specialty testing platforms from Siemens Healthineers. "This level of insight is now accessible on our established laboratory analyzer to help more patients get the answers they need, faster and more affordably."

The 3gAllergy assay from Siemens Healthineers is an allergen-specific IgE test that aids physicians in identifying, monitoring, and managing patients with allergic diseases. The nine new component allergens added to the 3gAllergy menu are CE marked and now widely available. More information is available [here](#).

1 [The global burden of illness of peanut allergy: A comprehensive literature review.](#)

2 Availability varies by country. These allergens are not available for sale in the U.S.

3 [Global Allergy & Airways Patient Platform](#)

A press picture is available [here](#).

Media contact

Kimberly Nissen

+1 610 241-2129; kimberly.nissen@siemens-healthineers.com

Visit the [Siemens Healthineers Press Center](#).

Subscribe to our [“Medtech matters” newsletter on LinkedIn](#).

Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2024, which ended on September 30, 2024, Siemens Healthineers had approximately 72,000 employees worldwide and generated revenue of around €22.4 billion. Further information is available at www.siemens-healthineers.com.